1. Introduction {#s0005}
===============

Small cell carcinoma of cervix (SmCC) is a relatively rare subtype in the spectrum of cervical malignancies ([@bb0140]). It accounts for approximately 2--5% of all cervical malignancies ([@bb0085]; [@bb0005]; [@bb0115]). SmCC, however, is far more aggressive compared to the more common variants such as squamous cell carcinoma, and these patients are more likely to develop lymph-node and distant metastasis ([@bb0120]; [@bb0010]). Several case series have reported relatively poor outcomes despite aggressive combined modality treatment ([@bb0015]; [@bb0125]; [@bb0180]). Cohen et al., in their literature review of 188 patients, reported 5-year disease-specific survival of 36.8%, 9.8%, and 0%, in stage I-IIA, IIB-IVA, and IVB respectively ([@bb0025]). Furthermore, due to rarity of this entity, management recommendations are based on retrospective institutional studies and often guided by the treatment protocols in small-cell lung cancer. The generalizability of those recommendations is debateable, and there remains a need for further studies to establish clinical parameters, prognosis, and outcomes in a wider population of patients. We report the results of a population-based study form a cancer registry database, to describe demographics, patterns of care and survival of patients of SmCC treated with radical intent chemo-radiotherapy on standardized provincial treatment protocols.

2. Materials and methods {#s0010}
========================

Approval was obtained from the University Research Ethics Board to review our provincial cancer registry for all patients of cervical cancer treated with radical radiotherapy including brachytherapy (with or without chemotherapy) from January 1, 1994 to December 31, 2013. These patients were treated in the six regional cancer centers of the province operated by British Columbia Cancer (BC Cancer). Uniform provincial management guidelines set by experts from all six cancer centers were followed. The histopathologic diagnosis of SmCC was primarily based on light microscopic findings and immunohistochemical markers like synaptophysin, chromogranin or CD56. Electron microscopy was not used. These patients were primarily seen by a Gynecological Oncologist and after discussion in a multidisciplinary tumor board they were subsequently referred to Medical and Radiation Oncologists. We included all patients with a small cell neuroendocrine component in the histopathology report and treated with primary radiotherapy (with or without concomitant chemotherapy) for this review. Patients who were treated primarily with hysterectomy were not included in this study. A total of 25 consecutive patients of SmCC treated with primary radiotherapy were identified and included in our analysis. Patient, tumor and treatment details, as well as outcomes were verified from computerized medical records or paper charts.

Patients were staged using Federation Internationale Gynecologica Obstetrica (FIGO) staging system. Staging evaluation included contrast enhanced computed tomography (CECT) of head, chest, abdomen and pelvis. Further investigations like magnetic resonance imaging of brain, examination under anesthesia or ultrasonography of abdomen was carried out based on individual physician discretion.

Standard chemotherapy protocol (*n* = 20; 80%) consisted of intravenous (IV) Paclitaxel (175 mg/m^2^) on day 1 and 98; IV Cisplatin 60 mg/m^2^ on day 1,2,21,22; IV Etoposide 75 mg/m^2^ on day 21,22; etoposide 100 mg orally on day 23--25 and day 126--130; IV Cisplatin 40 mg/m^2^ on day 42, 49, 56, 63, 70; IV Carboplatin (area under curve 5/6) on day 98 and 126. There were no planned dose reductions, but instead, treatment on days 21, 98, and 126 were delayed, if required, until the absolute neutrophil count was \>1000/cubic millimetre (cmm) and the platelet count was \>100,000/cmm. External beam radiation treatment (EBRT) typically began on day 42 concurrently with third cycle of chemotherapy. PCI, when used, was delivered after the completion of EBRT and brachytherapy (day 130--144). The dose-fraction schedule for PCI was 25 Gy in 10 fractions over two weeks. Use of PCI was at the discretion of the treating Radiation Oncologist.

Patients diagnosed before 1996 were treated with an alternate chemotherapy regimen, which included IV injection of etoposide (40 mg/m^2^/day) and cisplatin (25 mg/m^2^/day) for 5 consecutive days starting on days 1, 15, 29, and 43. EBRT started on day 15. PCI, if used, started on day 46. This was used in 5 patients.

EBRT target volume consisted of whole pelvis (consisting primary tumor and pelvic lymph node stations i.e. obturator, internal, external and common iliac, and upper pre-sacral nodes) (*n* = 9; 36%) or whole pelvis with para-aortic nodal basin starting from the lower border of 12th thoracic vertebra to the junction of L5/S1 (*n* = 16; 64%). Total dose ranged from 40 to 45 Gy in 20--25 fractions delivered over 4--5 weeks. For majority of patients, virtual simulation was used to design anterior and posterior beams, avoiding the kidneys with MLC shielding. However, patients in recent years have received conformal radiation using intensity modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT). Brachytherapy was delivered using two sessions of remote after-loading low-dose rate (LDR) technique using Cesium-137 prior to 2008. The dose prescription was 13.5 Gy to point A in each session. Since 2008, patients have received 5 fractions of high-dose rate (HDR) technique using Iridium-192, 6 Gy delivered in each fraction. The fractions of brachytherapy were often interdigitated with EBRT schedule. Overall, 20 (80%) patients received LDR brachytherapy while HDR brachytherapy was used in 5 (20%) patients.

Descriptive statistics were used to calculate the incidence, prevalence and other demographic characteristics of the study population. Comparison of categorical variables was carried out using chi-square test. Progression free survival (PFS) was defined as the period from the date of diagnosis to the date of progression or last follow-up. Overall survival (OS) was defined as the period from the date of diagnosis to death or last follow-up. PFS and OS estimation was done using the Kaplan-Meier method and association of prognostic factors with survival was estimated using the log-rank test. All reported *p*-values were two sided. A p-value of \<0.05 was considered significant. The SPSS® v. 14.0 (IBM Corp., New York, NY; formerly SPSS Inc., Chicago, IL) was used for all statistical analyses.

3. Results {#s0015}
==========

3.1. Patients {#s0020}
-------------

A total of 25 patients was included in the study. Of note, over 1200 patients with cervical malignancies were treated with radical radiotherapy in the province over the study period. The median age of patient was 41 (range: 23--80). Pure small cell carcinoma was noted in 17 (68%) patients while 6 (24%) patients had additional neuroendocrine component. Mixed adenocarcinoma with SmCC was noted in 2 (8%) patients. Majority of patients (*n* = 20; 80%) had high grade cancer, rest (*n* = 5, 20%) had intermediate grade. Most (*n* = 16; 64%) of the patients had early stage (stage I-IIA) disease: stage IB (*n* = 12; 48%) and IIA (*n* = 4; 16%). Stage IIB, IIIB and IVB disease were identified in 5 (20%), 3 (12%) and 1 (4%) patients respectively. Overall 7 (28%) patients had radiographically node-positive (N+) disease while 18 (72%) had node-negative (N-) disease. Five out of 7 (71%) (N+) patients had combined pelvic and para-aortic EBRT and 2 had pelvic EBRT (29%). A total of 11 out of 18 (61%) (N-) patients underwent pelvic and para-aortic EBRT while 7 (39%) had pelvic EBRT. Total 24 (96%) patients completed the full course of EBRT and brachytherapy; one patient did not receive full course EBRT due to interim disease progression. PCI was used in 6 (24%) patients after completion of loco-regional EBRT. A total of five (20%) patients had salvage surgery after completion of chemo-radiotherapy.

3.2. Pattern of failure {#s0025}
-----------------------

After a median follow-up duration of 54 months (range: 4.5--270.9 months), 15 (60%) patients had disease progression; 12 (48%) patients had distant metastasis. Isolated distant metastasis was seen in 6 (24%) patients, combined distant and nodal metastasis was noted in 5 (20%) patients, and combined local, nodal and distant failure was noted in 1 (4%) patient. One (4%) patient had disease progression locally and in pelvic nodes. Isolated local and isolated nodal metastasis were identified in 1 (4%) patient each. The frequent sites of distant metastasis were liver (*n* = 4), brain (*n* = 3), bone (*n* = 2), lung/pleural metastasis (n = 2), bone marrow (*n* = 1).

There was no difference in local failure rate between patients treated with pelvic EBRT (n = 1; 11%) and combined pelvic & para-aortic EBRT (*n* = 2; 12.5%). Nodal failure rate was also comparable between the combined pelvic & para-aortic (*n* = 6; 37.5%) and pelvic EBRT group (*n* = 3; 33%). Among 6 patients with nodal failures in the combined pelvic & para-aortic EBRT group, 3 (50%) had (N+) disease on the pre-treatment staging while among 3 patients with nodal failure in the pelvic EBRT group, 1 (33%) had (N+) disease. The sites of nodal failure in patients treated with pelvic EBRT included retroperitoneal chain (*n* = 1) and supraclavicular fossa (n = 1) respectively. For those who had combined pelvic and para-aortic EBRT, 3 had failure in retroperitoneal chain, 2 in both retroperitoneal and pelvic nodal areas and 1 in supraclavicular fossa.

Overall incidence of distant failure (*n* = 1; 16.67% vs. *n* = 11; 57.9%) and intra-cranial failure (0% vs. *n* = 3; 15.8%) were less in patients who had PCI compared to those treated without PCI.

3.3. Survival analysis {#s0030}
----------------------

At the time of analysis, 16 (64%) patients had died. 13 (81.3%) had deaths related to their primary cancer, remaining 3 (18.7%) died from second malignancies (colon cancer, ovarian carcinoma and leukemia, respectively). The 5-year OS and PFS were 48% and 46.4%, respectively ([Fig. 1](#f0005){ref-type="fig"}). On univariate analysis we found that patients with stage I-IIA disease had superior 5-year PFS (67.3% vs. 11.1%; *p* = .004) and 5-year OS (62.5% vs. 22.2%; *p* = .006). Patients with radiographic (N-) disease had a trend towards better 5-year PFS (55.7% vs. 19%; *p* = .07) and OS (61.1% vs. 14.3% at 5-years; *p* = .06) ([Fig. 2](#f0010){ref-type="fig"}). Patients treated with pelvic & paraaortic EBRT had 5-year OS and PFS of 56.3% and 50% compared to 40% and 33.3% in patients treated with pelvic EBRT. Patients with ≤40 years of age had 5-year OS and PFS of 85% and 82% compared to 69% and 64% in patients older than 40 years. There were no significant differences among the groups on log-rank test. Patients treated with PCI had numerically superior OS (67% vs. 39%, *p* = .09) and PFS (67% and 36%, *p* = .142). The results of log-rank tests have been summarized in [Table 1](#t0005){ref-type="table"}.Fig. 1Overall survival and progression free survival.Fig. 1Fig. 2Impact of stage and nodal involvement on overall and progression free survival.Fig. 2Table 1Result of univariate analysis (log-rank test).Table 1Factors5-yr PFS'p' value5-year OS'p' valueAge ≤4082%0.46185%0.474 \>4064%69%RT target volume Pelvic + Para-aortic50%0.69956.3%0.444 Pelvic alone40%33.3%Delay in start of Rx: ≤1 month44.2%0.58856%0.444 \>1 month50%33%Stage: I-IIA55.7%0.00462.5%0.006 IIB0%22.2%Node involvement No (N-)\
 Yes (N+)55.7%\
19%0.0761.1%\
14.3%0.06Prophylactic cranial RT Used66.7%0.14266.7%0.09 Not-used36.4%38.9%Presence of NEC No47.4%0.25452.6%0.210 Yes50%33%[^1]

A comparative description of outcome in available literature on SmCC ([@bb0010]; [@bb0180]; [@bb0025]; [@bb0045]; [@bb0060]; [@bb0020]; [@bb0150]; [@bb0155]; [@bb0040]; [@bb0070]; [@bb0055]; [@bb0130]; [@bb0105]; [@bb0050]; [@bb0170]; [@bb0095]; [@bb0080]; [@bb0065]) have been summarized in [Table 2](#t0010){ref-type="table"}.Table 2Other studies of Small cell carcinoma of cervix.Table 2AuthorsYear of publicationPatientsTreatment usedMedian follow-upSurvival outcomeStage-wise survivalBoruta et al. ([@bb0010])/USA200134Sx + Adj. CTx--OS at 2-years: 38%--Vishwanathan et al. ([@bb0150])/USA200421Mixed83 mo. (surviving pts)OS at 5-years: 29%--Zivanovic et al. ([@bb0180])/USA200917Mixed21 mo.(surviving pts)OS at 3-years: 30%\
PFS at 3-years: 22%--Cohen et al. ([@bb0025])/literature review2010188MixedN/A--5-year DFS:\
I-IIA: 36.8%\
IIB-IV: 8.9%Chen et al. ([@bb0020])/SEER2008290Mixed14.5 mo.OS at 5-years: 35.7%--Lee et al. ([@bb0055])/Korea200868 (stage IB-IIA)Sx ± Adj. treatment44 mo.OS at 5-years: 46.6%--Wang et al. ([@bb0155])/Taiwan2012179Mixed51.2 mo. (surviving pts)Median CSS: 24.8 mo.\
Median FFS: 16 mo.I (51.1%)\
II (50.4%)\
III (13%)\
IV (6%)Peng et al. ([@bb0105])/China201214 (NEC)Sx ± Adj. treatment10 mo.Median OS: 32 mo.\
Median DFS: 6 mo.--Kuji et al. ([@bb0045])/Japan201352Mixed57 mo.--4-year OS & PFS:\
IB1: 63%, 59%\
IB2: 67%, 68%\
IIB: 30%, 13%\
IIIB: 29%, 17%\
IVB: 25%Stecklein et al. ([@bb0130])/USA201640 (NEC)Mixed21.5 mo.OS at 5-years: 27%\
EFS at 5-years: 20%Median OS:\
≤ Stage IB1: 41 mo.\
≥ Stage IB2: 17 mo.Lan Fang et al. ([@bb0050])/China201243----OS at 5-years: 29%Median OS:\
Early stage: 89.6 mo.\
Late stage: 34.4 mo.Lee et al. ([@bb0060])/Korea2015102Mixed----Median OS & TTP:\
Early stage: 40.7 & 22.3 mo.\
Late stage: 21.4 & 13.3 mo.Yuan et al. ([@bb0170])/China201538 (Stage IA-IIA)Sx ± Adj. CTx--OS at 5-years: 43%\
Median DFS: 36 mo.--Nagao et al. ([@bb0095])/Japan201523Mixed24 mo.5-year OS:\
Small cell NEC-19%\
Large cell NEC: 91%--Li et al. ([@bb0070])/China201522Mixed24.1 mo.OS at 3-years: 55%\
DFS at 3-years: 50%3-year OS:\
Early stage: 68%\
Late stage: 0%Huang et al. ([@bb0040])/China201472Mixed--4-year OS:\
IB1: 63%\
IB2: 67%\
IIB: 30%\
IIIB: 29%\
IVB:25%McCann et al. ([@bb0080])/USA201326Mixed27 mo.--Median OS:\
Stage I: NR\
Stage II-IV: 12.1 moLee et at ([@bb0065])/Korea201661Sx ± Adj. Tx----5-year OS:\
Early-42.1%, Late-23.7%Roy et al./current study--25CTx + RT ± PCI54 mo.OS at 5-years: 48%\
PFS at 5-years: 46.4%5-year PFS & OS:\
Stage I-IIA: 55.7% & 62.5%\
Stage IIB-IVB: 0% & 22.2%[^2]

4. Discussion {#s0035}
=============

The current study describes the outcomes of a cohort of SmCC treated with radical chemo-radiation in our province. The findings of our study consolidate the results of the study by Hoskins et al. ([@bb0035]). Patients in our study were treated radically using uniform chemo-radiotherapy protocol across the province. The follow-up duration in our study is relatively longer compared to other reports and the survival figures and overall failure rates are in agreement with available literature ([@bb0180]; [@bb0150]; [@bb0155]). We found distant metastasis to be the predominant pattern of disease progression while stage and nodal involvement were noted to have association with survival. These findings are also in accordance with existing studies ([@bb0025]; [@bb0045]; [@bb0020]; [@bb0155]; [@bb0040]; [@bb0070]; [@bb0055]).

Radiation therapy plays a pivotal role in the management of SmCC. The survival outcome in our series which primarily includes a cohort of patients treated with chemo-radiation, is compatible with that from other surgical series ([@bb0045]; [@bb0055]; [@bb0065]). This highlights the efficacy of EBRT as a loco-regional treatment modality. Other studies including a large Taiwanese Gynecologic Oncology Group (TGOG) ([@bb0155]) study have established the efficacy of concurrent chemo-radiation in the treatment of SmCC. Chen et al. reported a lower locoregional failure rate in patients who received primary radiotherapy than those who had primary surgery in stage I-II SCCC (6% vs. 27%, *P* = .009) ([@bb0020]). However, none of these studies described the ideal target volume of radiotherapy for these patients. Radiation target volume needs to be tailored depending on overall tumor stage including nodal involvement, use of chemotherapy and individual tolerance.

Our study shows improved distant control, intracranial disease control and a numerically superior overall survival with PCI. However, there are underlying confouding factors including non-random patient allocation and limited sample size. Moreover, the overall rate of intracranial failure is only 12% at 5-years which is comparable to other series on extra-pulmonary small cell carcinoma (EPSCC) ([@bb0030]; [@bb0100]; [@bb0090]). However, these patients did not undergo serial brain imaging during their follow-up and therefore the failure rate should be interpreted with caution. Naidoo et al. ([@bb0100]) studied 280 patients of EPSCC. Approximately 66% belonged to extensive stage and 17 (6%) had primary cervical SmCC. They found an intra-cranial metastasis rate of 6.5%. Another study by De Caluwé et al. ([@bb0030]) estimated the incidence of symptomatic brain metastasis from a cohort of EPSCC. The overall rate of brain metastasis was 12.5% at 3-years. In PCI Eligible patients, defined as patients with non-metastatic EPSCC who received local or systemic treatment, or metastatic EPSCC who responded to systemic treatment, the 3-year cumulative incidence of new brain metastases was 5.5% for non-metastatic cohorts and 26.3% for M1 disease. The 3-year cumulative incidence of brain metastasis in patients with cervical SmCC was 8.7%. In the absence of prospective studies, the findings of these large retrospective series allude to a relatively low rate of intra-cranial metastasis in EPSCC. Moreover, several studies have highlighted the long-term neurocognitive effect of PCI including significant decline in memory (both immediate and delayed recall) in patients with lung cancer ([@bb0135]; [@bb0165]). Therefore, PCI might be dispensable in primary SmCC, but should always be discussed as part of multi-modality management protocol.

In our cohort, the use of complex multi-agent chemotherapy regimen was reasonably well tolerated and outcomes were comparable to historic cohorts ([@bb0035]). A cisplatin/etoposide (EP) regimen similar to that used for small cell lung cancer, however, may be most widely used and is described in Gynecologic Cancer Inter Group (GCIG) Consensus Review ([@bb0145]; [@bb0110]). In retrospective studies and systematic reviews, an addition of platinum-based chemotherapy in pre-operative or post-operative setting was associated with improved OS and PFS ([@bb0145]; [@bb0075]; [@bb0175]). Similarly, concurrent chemotherapy may improve survival outcomes in conjunction with radiation therapy, although no level I evidence exists to demonstrate what constitutes an optimal regimen. In setting of concurrent chemoradiation, at least one retrospective study identified that receipt of 5 or more cycles of EP was associated with significantly better 5-year failure-free survival and cancer-specific survival ([@bb0160]). In the absence of evidence from direct comparison, the addition of a platinum-based chemotherapy regimen is generally accepted as standard of care in this context.

Some of the limitations of the current study include its retrospective nature, limited patient number, lack of comprehensive information about quality of life parameters including treatment related toxicities and neurocognitive effects of PCI among others.

Despite these caveats, we conclude that combined modality treatment using multi-agent platinum-based chemotherapy and loco-regional radiotherapy remains cornerstone of non-surgical management for patients with small cell carcinoma of the cervix. Role of PCI is controversial. With modern chemo-radiotherapy protocols we can expect a 5-year survival of around 50%. Stage and nodal involvement bear significant correlation with survival and these factors should be given consideration while customizing treatment.
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[^1]: PFS: progression free survival; OS: overall survival; RT: radiotherapy; NEC: neuro-endocrine carcinoma component.

[^2]: Mo.: months; Sx: surgery; Adj: adjuvant; CTx: chemotherapy; RT: radiotherapy; NEC: neuro-endocrine carcinoma; pts.: patients; OS: overall survival; PFS: progression free survival; DFS: disease specific survival; CSS: cancer specific survival; FFS: failure free survival; EFS: event free survival; TTP: time to progression; NR: not reached; PCI: Prophylactic cranial irradiation.
